Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Costs and Barriers of Cancer Screening After Positive Genetic Testing: Are Actionable Mutations Becoming "Unactionable"?

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Jun 2022

Kahn Ryan M, Gordhandas Sushmita, Aviki Emeline, Long Roche Kara

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Early Detection of Cancer
Share to Genetic Testing
Share to Mutation
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35714670
DOI: 10.6004/jnccn.2022.7013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Costs and Barriers of Cancer Screening After Positive Genetic Testing: Are Actionable Mutations Becoming "Unactionable"?PMID 35714670Read ↗

Call for action: expanding global access to hereditary cancer genetic testing.Semantic proximity Read ↗

Banishing biases to save lives: introducing genetic testing for familial cancers.Semantic proximity Read ↗

Medicare-funded cancer genetic tests: a note of caution.Semantic proximity Read ↗

Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics.Semantic proximity Read ↗

The changing landscape of hereditary cancer genetic testing.Semantic proximity Read ↗

Most patients with cancer are not undergoing germline genetic testing.Semantic proximity Read ↗

Can we really afford to spend NHS cash on genetic testing for cancer?Semantic proximity Read ↗

Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare CostsSemantic proximity Read ↗

Barriers, interventions, and recommendations: Improving the genetic testing landscapeSemantic proximity Read ↗

Predictive genetic testing for childhood cancer: taking the road less traveled by.Semantic proximity Read ↗

Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.Semantic proximity Read ↗

Screening for disease: how far is too far?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.